Loading clinical trials...
Loading clinical trials...
Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)
Conditions
Interventions
Ranolazine
Verapamil
+4 more
Locations
1
United States
Spaulding Clinical Research
West Bend, Wisconsin, United States
Start Date
March 14, 2017
Primary Completion Date
June 26, 2017
Completion Date
June 26, 2017
Last Updated
January 18, 2020
NCT07052162
NCT04961593
NCT02456974
NCT06426836
NCT06993636
NCT03717623
Lead Sponsor
Food and Drug Administration (FDA)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions